MAPK pathways regulation by DUSP1 in the development of osteosarcoma: Potential markers and therapeutic targets

Molecular Carcinogenesis

Volumn 56, Issue 6, 2017, Pages 1630-1641

  Lopes, Luana Joyce Silva ^a   Tesser Gamba, Francine ^a   Petrilli, Antônio Sérgio ^a   de Seixas Alves, Maria Teresa ^a   Garcia Filho, Reynaldo Jesus ^a   Toledo, Silvia Regina Caminada ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

biomarkers; DUSP1; MAPK signaling pathways; osteosarcoma; therapeutic target

Indexed keywords

BETA ACTIN; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 5; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; MYOCYTE ENHANCER FACTOR 2; MYOCYTE ENHANCER FACTOR 2A; MYOCYTE ENHANCER FACTOR 2C; MYOCYTE ENHANCER FACTOR 2D; PROTEIN BAD; PROTEIN FOS; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; STRESS ACTIVATED PROTEIN KINASE 1; TRANSCRIPTION FACTOR ELK 4; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DUSP1 PROTEIN, HUMAN; MAP2K6 PROTEIN, HUMAN; MAP4K3 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; DOWN REGULATION; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; OVERALL SURVIVAL; PREOPERATIVE CHEMOTHERAPY; PRIORITY JOURNAL; TUMOR NECROSIS; BONE; BONE NEOPLASMS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; INFANT; MAPK SIGNALING; METABOLISM; PATHOLOGY; PRESCHOOL CHILD; PREVENTION AND CONTROL; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BONE AND BONES; BONE NEOPLASMS; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; DUAL SPECIFICITY PHOSPHATASE 1; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFANT; MALE; MAP KINASE KINASE 6; MAP KINASE SIGNALING SYSTEM; NEOPLASM INVASIVENESS; OSTEOSARCOMA; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 85013640579     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22619     Document Type: Article

References (54)

1. Campanacci M. Bone and Soft Tissue Tumors: Clinical Features, Imaging, Pathology, and Treatment. 2nd ed. Wien, Austria: Springer-Velag; 1999.
2. Hayden JB, Hoang BH. Osteosarcoma: basic science and clinical implications. Orthop Clin North Am. 2006; 37:1–7.
3. Picci P. Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis. 2007; 2:6.
4. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009; 152:3–13.
5. Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin North Am. 1997; 44:973–989.
6. Link MP, Gebhardt MC, Eilber F. Principles and Practice of Pediatric Oncology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2002.
7. Martin JW, Squire JA, Zielenska M. The genetics of osteosarcoma. Sarcoma. 2012; 2012:Article ID 627254. https://doi.org/10.1155/2012/627254
8. Scotlandi K, Serra M, Nicoletti G, et al. Multidrug resistance and malignancy in human osteosarcoma. Cancer Res. 1996; 56:2434–2439.
9. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004; 9:422–441.
10. Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment—where do we stand? A state of the art review. Cancer Treat Rev. 2014; 40:523–532.
11. Clark JC, Dass CR, Choong PF. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol. 2008; 134:281–297.
12. Maire G, Martin JW, Yoshimoto M, Chilton-MacNeill S, Zielenska M, Squire JA. Analysis of miRNA-gene expression-genomic profiles reveals complex mechanisms of microRNA deregulation in osteosarcoma. Cancer Genet. 2011; 204:138–146.
13. PosthumaDeBoer J, Witlox MA, Kaspers GJ, van Royen BJ. Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clin Exp Metastasis. 2011; 28:493–503.
14. Lei YY, Wang WJ, Mei JH, Wang CL. Mitogen-activated protein kinase signal transduction in solid tumors. Asian Pac J Cancer Prev. 2014; 15:8539–8548.
15. Yang R, Piperdi S, Gorlick R. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma. Clin Cancer Res. 2008; 14:6396–6404.
16. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell. 2000; 103:239–252.
17. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001; 410:37–40.
18. Wang X, Tournier C. Regulation of cellular functions by the ERK5 signalling pathway. Cell Signal. 2006; 18:753–760.
19. Nishimoto S, Nishida E. MAPK signalling: ERK5 versus ERK1/2. EMBO Rep. 2006; 7:82–86.
20. Keyse SM. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev. 2008; 27:253–261.
21. Tesser-Gamba F, Petrilli AS, de Seixas Alves MT, Filho RJ, Juliano Y, Toledo SR. MAPK7 and MAP2K4 as prognostic markers in osteosarcoma. Hum Pathol. 2012; 43:994–1002.
22. Lawan A, Shi H, Gatzke F, Bennett AM. Diversity and specificity of the mitogen-activated protein kinase phosphatase-1 functions. Cell Mol Life Sci. 2013; 70:223–237.
23. Boutros T, Chevet E, Metrakos P. Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacol Rev. 2008; 60:261–310.
24. Keyse SM. The role of protein phosphatases in the regulation of mitogen and stress-activated protein kinases. Free Radic Res. 1999; 31:341–349.
25. Wancket LM, Frazier WJ, Liu Y. Mitogen-activated protein kinase phosphatase (MKP)-1 in immunology, physiology, and disease. Life Sci. 2012; 90:237–248.
26. Loda M, Capodieci P, Mishra R, et al. Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. Am J Pathol. 1996; 149:1553–1564.
27. Liao Q, Guo J, Kleeff J, et al. Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells. Gastroenterology. 2003; 124:1830–1845.
28. Chattopadhyay S, Machado-Pinilla R, Manguan-Garcia C, et al. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer. Oncogene. 2006; 25:3335–3345.
29. Tai CJ, Wu AT, Chiou JF, et al. The investigation of mitogen-activated protein kinase phosphatase-1 as a potential pharmacological target in non-small cell lung carcinomas, assisted by non-invasive molecular imaging. BMC Cancer. 2010; 10:95.
30. Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med. 1977; 101:14–18.
31. Mortus JR, Zhang Y, Hughes DP. Developmental pathways hijacked by osteosarcoma. Adv Exp Med Biol. 2014; 804:93–118.
32. Lam D, Dickens D, Reid EB, Loh SH, Moisoi N, Martins LM. MAP4K3 modulates cell death via the post-transcriptional regulation of BH3-only proteins. Proc Natl Acad Sci USA. 2009; 106:11978–11983.
33. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009; 9:537–549.
34. Parray AA, Baba RA, Bhat HF, et al. MKK6 is upregulated in human esophageal, stomach, and colon cancers. Cancer Invest. 2014; 32:416–422.
35. Bermudez O, Pages G, Gimond C. The dual-specificity MAP kinase phosphatases: critical roles in development and cancer. Am J Physiol Cell Physiol. 2010; 299:C189–C202.
36. Sanchez-Perez I, Martinez-Gomariz M, Williams D, Keyse SM, Perona R. CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin. Oncogene. 2000; 19:5142–5152.
37. Whitmarsh AJ. Regulation of gene transcription by mitogen-activated protein kinase signaling pathways. Biochim Biophys Acta. 2007; 1773:1285–1298.
38. Park KS, Lee NG, Lee KH, Seo JT, Choi KY. The ERK pathway involves positive and negative regulations of HT-29 colorectal cancer cell growth by extracellular zinc. Am J Physiol Gastrointest Liver Physiol. 2003; 285:G1181–G1188.
39. Maldonado JL, Timmerman L, Fridlyand J, Bastian BC. Mechanisms of cell-cycle arrest in Spitz nevi with constitutive activation of the MAP-kinase pathway. Am J Pathol. 2004; 164:1783–1787.
40. McMullen ME, Bryant PW, Glembotski CC, Vincent PA, Pumiglia KM. Activation of p38 has opposing effects on the proliferation and migration of endothelial cells. J Biol Chem. 2005; 280:20995–21003.
41. Valledor AF, Arpa L, Sanchez-Tillo E, et al. IFN-(gamma)-mediated inhibition of MAPK phosphatase expression results in prolonged MAPK activity in response to M-CSF and inhibition of proliferation. Blood. 2008; 112:3274–3282.
42. Chandran UR, Ma C, Dhir R, et al. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer. 2007; 7:64.
43. Song JY, Lee JK, Lee NW, Jung HH, Kim SH, Lee KW. Microarray analysis of normal cervix, carcinoma in situ, and invasive cervical cancer: identification of candidate genes in pathogenesis of invasion in cervical cancer. Int J Gynecol Cancer. 2008; 18:1051–1059.
44. Huang C, Jacobson K, Schaller MD. MAP kinases and cell migration. J Cell Sci. 2004; 117:4619–4628.
45. Moncho-Amor V, Ibanez de Caceres I, Bandres E, et al. DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer. Oncogene. 2011; 30:668–678.
46. Reddy KB, Nabha SM, Atanaskova N. Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev. 2003; 22:395–403.
47. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007; 26:3279–3290.
48. Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 2010; 1802:396–405.
49. Tesser-Gamba F, Lopes LJS, Petrilli AS, Toledo SR. MAPK7 gene controls proliferation, migration, and cell invasion in Osteosarcoma. Mol Carcinog. 2015; 55:1700–1713.
50. Wilkinson MG, Samuels M, Takeda T, et al. The Atf1 transcription factor is a target for the Sty1 stress-activated MAP kinase pathway in fission yeast. Genes Dev. 1996; 10:2289–2301.
51. Schaeffer HJ, Weber MJ. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol. 1999; 19:2435–2444.
52. Sun H, Charles CH, Lau LF, Tonks NK. MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell. 1993; 75:487–493.
53. Kinney CM, Chandrasekharan UM, Mavrakis L, Di Corleto PE. VEGF and thrombin induce MKP-1 through distinct signaling pathways: role for MKP-1 in endothelial cell migration. Am J Physiol Cell Physiol. 2008; 294:C241–C250.
54. Shen YH, Godlewski J, Zhu J, et al. Cross-talk between JNK/SAPK and ERK/MAPK pathways: sustained activation of JNK blocks ERK activation by mitogenic factors. J Biol Chem. 2003; 278:26715–26721.